ENIM ET NEQUE FAUCIBUS

Your Partner in Infectious Diseases and Vaccines

The continued increase in antibiotic resistance, emergence and re-emergence of novel infectious disease reinforces the need to develop more safe, robust, and effective anti-infective therapies and vaccines. To protect people across the globe, particularly those who have inadequate access to medical care, our team is dedicated to advancing products that help prevent and treat bacterial, viral, fungal, and parasitic infections in community-based and critical care settings.

Learn how Fortrea's infectious disease and vaccine experts bring together decades of experience from large pharma, biotech and research organizations—spanning nonclinical and clinical development of products—to efficiently support your program.

Read more on our website

 

Contact a team member-1st Oct

 

Successful Phase 3 Trial for Complicated UTI

We’re excited to share an article from our collaboration with Venatorex, the sponsor of a phase three double-blind randomized clinical trial on complicated urinary tract infections, including pyelonephritis. This trial demonstrated the superiority of cefepime-taniborbactam over meropenem.

Want to dive deeper into this study? Check out the full article in the New England Journal of Medicine.

 

Navigating a dynamic study design in hepatitis B research

The successful execution of this platform study in hepatitis B research demonstrates the power of collaboration, expertise and adaptability in advancing complex clinical trials. At Fortrea, we are committed to supporting innovative research designs. By fostering strong relationships with sponsors and sites, embracing transparency and continuously refining our approaches, we aim to contribute to the efficient development of treatments that can make a significant difference in patients’ lives.


0001_Hep-B-CS
How Fortrea navigated complexities in a Phase I ICU trial

The landscape of ICU research, while challenging, offers immense potential for advancing critical care medicine. This Phase I trial for a novel treatment in mechanically ventilated patients illuminates several key lessons for conducting successful ICU clinical trials.

0003_Blog-cum-IS
Qualified infectious disease product designation: What’s to GAIN?

The Generating Antibiotic Incentives Now (GAIN) Act was signed into US law in 2012 to enrich the drug development pipeline targeted at resistant pathogens. GAIN positions incentives and provides additional guidance to sponsors developing antibacterial and antifungal drugs intended to address serious or life-threatening infections through a regulatory designation known as Qualified Infectious Disease Product (QIDP).

Image_2_cGMP
Rapid diagnostic advantages in clinical research

Integrating rapid diagnostics in infectious disease clinical trials marks an important advancement in research and management. Rapid diagnostic tests (RDTs) accelerate the accurate diagnosis of infections, enabling timely and targeted interventions. Furthermore, RDTs can streamline trial processes, facilitate real-time data collection, and enhance the overall efficiency of clinical studies.

069
Fortrea IDV Experience

Upcoming Webinar

Double Dippers: The Secret Lives of Serial Study Subjects

December 16, 2024

The objective of this webinar is to discuss several measures that can help prevent multiple enrollments and enhance patient safety as part of a structured Quality by Design initiative. The experts will also share proactive operational strategies from site selection techniques to protocol design. Finally, attendees will learn how detection technologies can help identify duplicate participants, confirm eligibility and ensure the selection of high-quality subjects. 

Implementing agile solutions to successfully deliver a vaccine clinical trial in China
This case study shares how Fortrea employed approaches to successfully deliver a Phase III industry-sponsored clinical trial, manage the inherent complexity of a vaccine trial and run a successful study.
 
China vaccine CS image
Navigating pediatric vaccine trials in LMIC
Pediatric vaccine trials in Low- and Middle-Income Countries (LMICs) offer opportunities to address global health disparities. Fortrea provides support for organizations conducting pediatric vaccine trials in LMICs. With experience in managing complex trials across diverse settings, Fortrea offers guidance on regulatory compliance, ethical considerations, and community engagement strategies. Contact us for more information on how Fortrea can assist with your research.
 
0002_Vaccine-WP
Fortrea Vaccines Experience
Do you need support navigating your clinical trial program?
Fill out the form below, and a member of our team will be in touch.